What are the major opportunities in the biologics market and the approaches companies can take to take advantage of them?

For this and further detailed insights on the market, request a sample here. Read More

Biologics Global Market Opportunities And Strategies To 2034

Name: Biologics Global Market Opportunities And Strategies To 2034
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Download Sample Buy Report

Biologics Market 2025 – By Type (Monoclonal Antibodies (MABS), Therapeutic Proteins And Vaccines), By Drug Classification (Branded Drugs, Generic Drugs), By Route Of Administration (Oral, Parenteral, Other Route Of Administration), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other Distribution Channels), And By Region, Opportunities And Strategies – Global Forecast To 2035

Biologics Global Market Opportunities And Strategies To 2034

Report Price : $4490.00 | Pages : 571 | Published : October 2025 | Delivery Time: Immediately | Format :

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Regional Data

FAQs

Biologics Market Definition

Biologics refer to a class of pharmaceutical products derived from living organisms or their components. Unlike chemically synthesized drugs, biologics include large, structurally intricate molecules such as monoclonal antibodies, therapeutic proteins, and vaccines. These products are primarily used in the treatment, prevention, or diagnosis of serious and chronic conditions such as cancer, autoimmune disorders, metabolic diseases, and infectious diseases. They are indispensable in modern medicine for their targeted action, high efficacy, and ability to treat previously untreatable conditions.

The biologics market consists of sales, by entities such as organizations, sole traders, and partnerships, of therapeutic products that are used in diverse medical settings, ranging from acute care hospitals and specialty clinics to community health centers and outpatient treatment facilities. They often complement other forms of therapy, such as conventional pharmaceuticals, surgery, or radiation therapy, and can sometimes replace older treatment regimens where higher efficacy or fewer side effects are desired.

Biologics Global Market Opportunities And Strategies To 2034 Market Size and growth rate 2025 to 2029: Graph

Biologics Market Size

The global biologics market reached a value of nearly $446,381.16 million in 2024, having grown at a compound annual growth rate (CAGR) of 8.23% since 2019. The market is expected to grow from $446,381.16 million in 2024 to $653,760.99 million in 2029 at a rate of 7.93%. The market is then expected to grow at a CAGR of 7.22% from 2029 and reach $926,234.00 million in 2034.

Growth in the historic period resulted from the increasing incidence of autoimmune disorders, expansion of pharmaceutical and biotechnology industries, rising healthcare expenditure and rising demand for personalized medicine. Factors that negatively affected growth in the historic period were high cost of biologic therapies and stringent regulatory standards.

Going forward, the rising prevalence of chronic diseases, increasing research and development investments by pharma companies, rise in aging population and rapid adoption of monoclonal antibodies will drive the growth. Factor that could hinder the growth of the biologics market in the future include cold chain and storage challenges, risk of cross-contamination and impact of trade war and tariff.

Biologics Market Drivers

The key drivers of the biologics market include:

Rising Prevalence Of Chronic Diseases

The rising prevalence of chronic diseases is anticipated to drive the growth of the biologics market in the coming years. Conditions such as cancer, diabetes, rheumatoid arthritis, cardiovascular disorders, and other long-term illnesses are becoming increasingly common, leading to a greater demand for targeted and effective therapies. Biologics, valued for their high specificity and ability to interact with complex biological systems, are increasingly favored over traditional small-molecule drugs for treating these conditions. With an aging global population and a surge in lifestyle-related health problems, both healthcare providers and pharmaceutical companies are prioritizing the development of innovative biologic therapies to meet growing medical needs. This escalating disease burden is spurring increased investment in biologics research, clinical trials, and manufacturing capabilities, thereby fueling the expansion of the biologics market. The rising prevalence of chronic diseases contribution during the forecast period in 2024 is 1.50%.

Biologics Market Restraints

The key restraints on the biologics market include:

Cold Chain And Storage Challenges

Cold chain and storage challenges are expected to hinder the growth of the biologics market. Due to their high sensitivity to temperature variations, biologics require strict cold storage conditions throughout manufacturing, transportation, and distribution. Ensuring a reliable cold chain significantly increases logistical complexity and cost, especially in regions with inadequate infrastructure. Any disruption in temperature control can compromise the safety and efficacy of biologic products, resulting in product loss, heightened regulatory oversight, and delays in market availability. These challenges can restrict geographic expansion and deter smaller companies from entering the market. Consequently, cold chain and storage limitations remain a major obstacle to the broader adoption and global distribution of biologic therapies. Growth affected by cold chain and storage challenges during the forecast period in 2024 is -2.00%.

Biologics Market Trends

Major trends shaping the biologics market include:

Enhancing Depth Sensing Accuracy Through Innovation

Companies operating in the biologics market are focusing on integration of biosimilar, to enhance treatment accessibility, reduce healthcare costs, and expand their product portfolios across chronic and immune-mediated disease segments. Biosimilars are biologic medicines that closely resemble an existing approved reference product in terms of safety, effectiveness, and quality, with no significant clinical differences. For instance, in April 2025, Biocon Biologics Ltd, an India-based biotechnology firm, launched the JOBEVNE, a biosimilar Bevacizumab for intravenous use. It is a recombinant humanized monoclonal antibody that acts as a vascular endothelial growth factor (VEGF) inhibitor, preventing the formation of new blood vessels (angiogenesis) essential for tumor growth. Its approval was supported by robust comparative data confirming its high similarity to Avastin, with no clinically meaningful differences in efficacy, safety, pharmacokinetics, or immunogenicity. With this launch, Biocon Biologics strengthens its U.S. oncology portfolio and continues its mission to improve access to cost-effective cancer therapies.

Major companies operating in the biologics market are focusing on integration of biosimilar, to enhance treatment accessibility, reduce healthcare costs, and expand their product portfolios across chronic and immune-mediated disease segments. Biosimilars are biologic medicines that closely resemble an existing approved reference product in terms of safety, effectiveness, and quality, with no significant clinical differences. For instance, in February 2025, Biocon Biologics Ltd, an India-based biotechnology firm, launched the YESINTEK. It is a biosimilar developed to treat a range of chronic autoimmune diseases. As a monoclonal antibody, it targets interleukin-12 (IL-12) and interleukin-23 (IL-23) key cytokines involved in driving inflammation in conditions such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Approved by the U.S. FDA in December 2024 and launched in February 2025, YESINTEK provides a cost-effective, clinically equivalent alternative to the reference biologic, Stelara. It is available in various formulations, including prefilled syringes and vials, and is supported by robust clinical evidence showing comparable efficacy, safety, pharmacokinetics, and immunogenicity to the originator.

Opportunities And Recommendations In The Biologics Market

Opportunities – Major companies operating in the biologics market are focusing on integration of biosimilar, to enhance treatment accessibility, reduce healthcare costs, and expand their product portfolios across chronic and immune-mediated disease segments. Biosimilars are biologic medicines that closely resemble an existing approved reference product in terms of safety, effectiveness, and quality, with no significant clinical differences. For instance, in February 2025, Biocon Biologics Ltd, an India-based biotechnology firm, launched the YESINTEK. It is a biosimilar developed to treat a range of chronic autoimmune diseases. As a monoclonal antibody, it targets interleukin-12 (IL-12) and interleukin-23 (IL-23) key cytokines involved in driving inflammation in conditions such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Approved by the U.S. FDA in December 2024 and launched in February 2025, YESINTEK provides a cost-effective, clinically equivalent alternative to the reference biologic, Stelara. It is available in various formulations, including prefilled syringes and vials, and is supported by robust clinical evidence showing comparable efficacy, safety, pharmacokinetics, and immunogenicity to the originator.

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the biologics companies to focus on biosimilar integration to expand access and portfolios, focus on expanding biosimilar integration to drive accessibility and growth, focus on expanding biosimilar portfolios to drive growth, focus on high-concentration formulation platforms, focus on viral vector platforms to drive gene therapy growth, focus on therapeutic proteins for accelerated growth, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use b2b promotions, focus on retail pharmacies for sustained growth, focus on the over-the-counter drugs segment.

Book your 30 minutes free consultation with our research experts

Contact Us

Biologics Market Segmentation
The biologics market is segmented by type, by drug classification, by route of administration, by mode of purchase and by distribution channel.

By Type –

The Biologics market is segmented by type into:

a) Monoclonal Antibodies (MABS)
b) Therapeutic Proteins And Vaccines

The biologics market is segmented by type into monoclonal antibodies (MAbS), therapeutic proteins and vaccines. The monoclonal antibodies (MAbS) market was the largest segment of the biologics market segmented by type, accounting for 54.04% or $241,240.69 million of the total in 2024. Going forward, the therapeutic proteins segment is expected to be the fastest growing segment in the biologics market segmented by type, at a CAGR of 10.61% during 2024-2029.

By Drug Classification –

The Biologics market is segmented by drug classification into:

a) Branded Drugs
b) Generic Drugs

The branded drugs market was the largest segment of the biologics market segmented by drug classification, accounting for 69.13% or $308,595.45 million of the total in 2024. Going forward, the generic drugs segment is expected to be the fastest growing segment in the biologics market segmented by drug classification, at a CAGR of 8.50% during 2024-2029.

By Route Of Administration –

The Biologics market is segmented by route of administration into:

a) Oral
b) Parenteral
c) Other Route Of Administration

The parenteral market was the largest segment of the biologics market segmented by route of administration, accounting for 93.00% or $415,131.57 million of the total in 2024. Going forward, the oral segment is expected to be the fastest growing segment in the biologics market segmented by route of administration, at a CAGR of 10.83% during 2024-2029.

By Mode Of Purchase –

The Biologics market is segmented by mode of purchase into:

a) Prescription-Based Drugs
b) Over-The-Counter Drugs
The prescription-based drugs market was the largest segment of the biologics market segmented by mode of purchase, accounting for 79.35% or $354,203.45 million of the total in 2024. Going forward, the over-the-counter drugs segment is expected to be the fastest growing segment in the biologics market segmented by mode of purchase, at a CAGR of 8.35% during 2024-2029.

By Distribution Channel –

The Biologics market is segmented by distribution channel into:

a) Hospital Pharmacies
b) Retail Pharmacies Or Drug Stores
b) Other Distribution Channels
The hospital pharmacies market was the largest segment of the biologics market segmented by distribution channel, accounting for 51.38% or $229,333.62 million of the total in 2024. Going forward, the retail pharmacies or drug stores segment is expected to be the fastest growing segment in the biologics market segmented by distribution channel, at a CAGR of 8.77% during 2024-2029.

By Geography - The Biologics market is segmented by geography into:

o Asia Pacific
• China
• India
• Japan
• Australia
• Indonesia
• South Korea
o North America
• USA
• Canada

o South America
• Brazil

o Western Europe
• France
• Germany
• UK
• Italy
• Spain

o Eastern Europe
• Russia

o Middle East
o Africa

North America was the largest region in the biologics market, accounting for 52.48% or $234,277.96 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the biologics market will be Africa and Middle East where growth will be at CAGRs of 11.82% and 10.05% respectively.
Biologics Market Competitive Landscape
Major Competitors are:
Pfizer Inc

Merck & Co. Inc

F. Hoffmann-La Roche AG

Johnson & Johnson

Regeneron Pharmaceutical Inc
Other Competitors Include:
AbbVie Inc.
Sanofi S.A.
Amgen Inc.
AstraZeneca plc
Bristol Myers Squibb Company
Innovent Biologics
Hengrui Pharma
Biocon
Indian Immunologicals Ltd (IIL)
Dr. Reddy’s Laboratories
Serum Institute of India
Zydus Cadila
Takeda Pharmaceutical
Daiichi Sankyo
Chugai Pharmaceutical (Roche subsidiary)
Samsung Biologics
Xbrane Biopharma AB
STADA
Celltrion
LG Chem Life Sciences
CSL Limited
Patheon (Thermo Fisher Scientific)
Lonza Biologics
Tessa Therapeutics
EnteroBiotix
Lonza Group AG
Sartorius AG
Bio-Rad Laboratories
Eppendorf AG
Miltenyi Biotec B.V. & Co. KG
Cytena GmbH
GE HealthCare
SGS S.A.
Aenitis Technologies
Bracco S.p.A.
Gilead Sciences
Renuron Group
Siemens Healthineers AG
Cytiva Europe GmbH
bioMérieux
Immersciobio GmbH
Ciloa
Differential Bio
GlaxoSmithKline Plc
Lilly
Teva Limited
Abbott Laboratories
Vectura Group Limited
Procos S.p.A.
BSP Pharmaceuticals S.p.A.
4Moving Biotech
Coriolis Pharma
Chiesi Farmaceutici S.p.A.
EXO Biologics
Chime Biologics
Polpharma Biologics
Bioton
Mabion
Richter Gedeon
Egis Pharmaceuticals
SOTIO
Zentiva
Wacker Chemie AG
Forge Biologics Holdings LLC
LOTTE Biologics
Pinnacle Biologics
Alvotech
Ultragenyx Pharmaceutical Inc.
Eurofins CDMO Alphora
Formycon AG
Fresenius Kabi
Viatris Inc.
Abzena
Biotimize
Richmond Pharmaceuticals
BioMarin Pharmaceutical
Bionovis
Artixio
MediWound Ltd
Tabuk Pharmaceuticals
SaudiVax
Pfizer
Kemwell
Juniper Biologics Pte Ltd
Afrigen Biologics and Vaccines
EVA Pharma
Dei BioPharma Ltd
Aspen Pharmacare

Author: Abdul Wasay

Biologics Market Size
The global biologics market reached a value of nearly $253,414.8 million in 2020, having increased at a compound annual growth rate (CAGR) of 8.7% since 2015. The market is expected to grow from $253,414.8 million in 2020 to $420,551.5 million in 2025 at a rate of 10.7%. The market is then expected to grow at a CAGR of 9.6% from 2025 and reach $664,744.2 million in 2030.
Growth in the historic period resulted from aging population, government initiatives, ability to command high prices, and increased need for immunology. The market was restrained by pricing pressure from regulators, and lack of awareness on biosimilars among primary care physicians and specialists.
Going forward increase in funding, technological advancements, increase in healthcare access, robust research and development activities for development of oral biologics, lean towards pills over injections, and increasing robust pipeline of biologics will drive the growth. Factors that could hinder the growth of the biologics market in the future include high stringency and low turnover for clinical trials, stringent regulations related to biosimilar approvals, prolonged production and approval time, and nomenclature challenges.
Biologics Market Drivers

The key drivers of the biologics market included:
Increase In funding
Increasing funding from public and private organizations for the development of vaccines against COVID-19 is expected to drive the market in the forecast period. The large amount of funding from the public and private organizations accelerates the process of drug development and supports research of new drugs. For instance, In 2020, MTF Biologics which is a global non-profit organization has awarded over $1 million in funding to 11 research studies across the US through its 2020 Extramural Research Grants Program. Wellcome Trust, a UK based research -charity and the Gates Foundation announced collaboration with the credit card company MasterCard in a $125 million push to speed up development of drugs and vaccines for treating COVID-19 infections. Also, the Bill & Melinda Gates Foundation committed around $200 billion for the development of vaccines for different diseases. Hence increasing public-private funding for life science research will enhance the research and development which will drive the growth of the biologics market.
Biologics Market Restraints

The key restraints on the biologics market include:
High Stringency And Low Turnover For Clinical Trials
For pharmaceutical drugs, clinical studies such as the pharmacokinetics - pharmacodynamics (PK-PD) studies can be carried out on healthy individuals, if it can be safely administered to the healthy population. PK studies determine the time the drug takes to get absorbed, distributed, metabolized, and excreted within the body, and PD studies determine the biochemical and physiological effect of the drug. However, for biological drugs, there are some key considerations regarding the selection of healthy individuals. This is mainly because healthy individuals may have a higher immunogenic response than the population with the disease, and sometimes the PK of the reference product is altered when administered to a healthy individual. This results in unreliable clinical data. Such hindrances may stall the progress of biological drugs development.
Biologics Market Trends
Major trends shaping the biologics market include the following –
Revised FDA Regulations To Facilitate Biologics Drug Development
The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics, can now be obtained from sources other than the FDA’s Center for Biologics Evaluation and Research (CBER), or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens. In addition, the FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products. The number of new drug approvals was 48 in 2019, and increased to 53 in 2020. The new biologic product approvals in 2019 were 10 and as of October 2020 new biologic product approvals were 9.
Higher Profit Margins For Biologics
Companies in the biologics market are generating high profit margins due to high prices of biologics and their effectiveness. According to Statista, the profit margin in Q2 2020 for a few of the US biologics companies are 99.22% for Bluebird Bio Inc., 88.83% for Biogen, 86.82% for Asterias Biotherapeutics, and 82.71% for Allergan. Biologics treatment being nearly 22 times costlier than small molecule, is expected to generate a higher profit margin of around 40% in the future. For instance, the Biologics segment of Biocon Limited, an India-based biopharmaceutical company, reported 29% profit margins in the third quarter of FY 2019-2020.
Opportunities And Recommendations In Biologics Market
Opportunities –The top opportunities in the biologics market segmented by type will arise in the monoclonal antibodies segment, which will gain $75,160.9 million of global annual sales by 2025. The top opportunities in the monoclonal antibodies market segmented by type will arise in the anti-cancer mabs segment, which will gain $40,412.7 million of global annual sales by 2025. The top opportunities in the therapeutic proteins market segmented by type will arise in the metabolic disorders therapeutic proteins segment, which will gain $23,961.4 million of global annual sales by 2025. The top opportunities in the vaccines market segmented by type will arise in the anti-infective vaccines segment, which will gain $13,307.5 million of global annual sales by 2025. The top opportunities in the biologics market segmented by route of administration will arise in the others segment, which will gain $164,888.7 million of global annual sales by 2025. The top opportunities in the biologics market segmented by drug classification will arise in the branded drugs segment, which will gain $130,303.2 million of global annual sales by 2025.The top opportunities in the biologics market segmented by mode of purchase will arise in the prescription drugs segment, which will gain $129,786.1 million of global annual sales by 2025. The top opportunities in the biologics market segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $79,943.8 million of global annual sales by 2025. The biologics market size will gain the most in the USA at $84,453.4 million.
Recommendations-To take advantage of the opportunities, the business research company recommends the biologics companies to focus on research & development, use of large molecules, focus on drug development for complex diseases, expand in emerging markets, set up authorized distributors and sales representatives, leverage online pharmacies, targeting local pharmacies to spread awareness, provide competitively priced offerings in low-income countries to reach new users, skimmed pricing for innovative drugs, direct-to-customer (DTC) advertising, participate in trade shows and events, increased requirement of R&D scientists.

Biologics Market Segmentation
The biologics market is segmented by type, by rote of administration, by drug classification, by mode of purchase and by distribution channel.
By Type-
The biologics market is segmented by type into
a. Therapeutic Proteins

1) Metabolic Disorders Therapeutic Proteins

2) Cancer Therapeutic Proteins

3) Cardiovascular Therapeutic Proteins

4) Immunological Therapeutic Proteins

5) Other Therapeutic Proteins

b. Monoclonal Antibodies (MAbS)

1) Anti-Cancer MAbs

2) Immunological MAbS

3) Anti-Infective Monoclonal Antibodies (MAbs)

4) Neuropharmacological MAbs

5) Cardiovascular And Cerebrovascular MAbS

6) Others - Monoclonal Antibodies (MAbs)

c. Vaccines

1) Anti-Infective Vaccines

2) Autoimmunity Vaccines

3) Others-Vaccines

The monoclonal antibodies market was the largest segment of the biologics market segmented by type, accounting for 42.8% of the total in 2020. Going forward, the monoclonal antibodies segment is expected to be the fastest growing segment in the biologics market segmented by type, at a CAGR of 11.1% during 2020-2025.
By Route Of Administration –
The biologics market is segmented by route of administration into

a. Oral

b. Others (IV and IP)

The others market was the largest segment of the biologics market segmented by route of administration, accounting for 98.5% of the total in 2020. Going forward, the others segment is expected to be the fastest growing segment in the biologics market segmented by route of administration, at a CAGR of 10.7% during 2020-2025.
By Drug Classification –
The biologics market is segmented by drug classification into

a. Branded Drugs

b. Generic Drugs

The branded drugs market was the largest segment of the biologics market segmented by drug classification, accounting for 80.0% of the total in 2020. Going forward, the generic drugs segment is expected to be the fastest growing segment in the biologics market segmented by drug classification, at a CAGR of 11.6% during 2020-2025.
By Mode Of Purchase –
The biologics market is segmented by mode of purchase into

a. Prescription Drugs

b. Over-The-Counter (OTC) Drugs

The prescription drugs market was the largest segment of the biologics market segmented by mode of purchase, accounting for 78.2% of the total in 2020. Going forward, the OTC drugs segment is expected to be the fastest growing segment in the biologics market segmented by mode of purchase, at a CAGR of 10.9% during 2020-2025.
By Distribution Channel –
The biologics market is segmented by application into

a. Hospital Pharmacies

b. Retail Pharmacies

c. Online Pharmacies

The hospital pharmacies market was the largest segment of the biologics market segmented by hospital pharmacies, accounting for 50.1% of the total in 2020. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the biologics market segmented by distribution channel, at a CAGR of 16.4% during 2020-2025.
By Geography -
The biologics market is segment by geography into

o North America

• USA
• Canada
• Mexico

o Western Europe,

• UK

• Germany

• France

• Italy

• Spain

• Austria

• Belgium

• Denmark

• Finland

• Ireland

• Netherlands

• Norway

• Portugal

• Sweden

• Switzerland

o Asia Pacific

• China

• India

• Japan

• Australia

• Indonesia

• South Korea

• Hong Kong

• Malaysia

• New Zealand

• Philippines

• Singapore

• Thailand

• Vietnam

o Eastern Europe

• Russia

• Czech Republic

• Poland

• Romania

o South America

• Brazil

• Argentina

• Chile

• Colombia

• Peru

• Venezuela

o Middle East

• Israel

• Saudi Arabia

• Turkey

• UAE

o Africa

• Egypt

• Nigeria

• South Africa

North America was the largest region in the global biologics market, accounting for 53.2% of the total in 2020. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, the fastest-growing regions in the biologics market will be South America and Asia-Pacific, where growth will be at CAGRs of 14.8% and 11.4% respectively during 2020-2025. These will be followed by Eastern Europe and Africa where the markets are expected to grow at CAGRs of 11.4% and 11.3% respectively during 2020-2025.
Biologics Competitive Landscape

Major Competitors are:

Merck & Co., Inc.

AbbVie Inc.

F. Hoffmann-La Roche AG

Johnson & Johnson

Pfizer Inc.

Other Competitors Include:

Bristol Myers Squibb Company

Sanofi S.A.

GlaxoSmithKline Plc.

Eli Lilly and Company

Amgen Inc.

Wockhardt

Zydus Cadilla

Asahi Glass Co. Ltd.

China Biologic Products Holdings Inc.

China Regenerative Medicine International

AstraZenaca

ABLbio

Adimmune

Henlius

Innovent Biologics

Bio-Thera

Hisun Pharma

3SBio

Beijing ShuangLu Pharmaceuticals

Qilu Pharmaceutical

Shanghai Fosun Pharmaceuticals

Biocon

Dr.Reddy’s

Mylan

Kyowa Hakko Kirin

Takeda

Mitsubishi Tanabe

AGC Biologics

Eli Lilly and Company, Inc.

Sanofi

Amgen Inc

AbbVie Inc

Biogen Idec

Bayer AG

Johnson & Johnson Services

Pfizer, Inc.

Novartis AG

BiosanaPharma

WuXi

GlaxoSmithKline

Teva UK Limited

AstraZeneca

Abbott Laboratories

Vectura Group

Roche

Fujifilm

Lonza

Seqens

Piramal Pharma Solutions

Corden Pharma

Procos SpA

BSP Pharmaceuticals.

Microgen

Geropharm

Valenta

NovaMedica

SynBio

Rani Therapeutics

Emisphere Technologies, Inc.

Enteris BioPharma

Allena Pharmaceuticals

Abbvie

Biogen Inc

Hypermarcas

Aché

Eurofarma and Teuto Brasileiro

BioMarin Pharmaceutical

BIONOVIS BRASIL

Ecopharm

Julphar

SPIMACO ADDWAEIH

Hikma Pharmaceuticals

BBI Solutions

Aspen Pharmacare

Amoun Pharmaceuticals CO Ltd

54gene

Baxter International

Altis Biologics

Cipla Medpro South Africa

Sanofi Genzyme

Table Of Contents
1 Executive Summary
1.1 Biologics – Market Attractiveness And Macro Economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
6.1 General Market Definition
6.2 Summary
6.3 Biologics Market Definition And Segmentations
6.4 Market Segmentation By Type
6.4.1 Monoclonal Antibodies (MAbS)
6.4.2 Therapeutic Proteins
6.4.3 Vaccines
6.5 Market Segmentation By Drug Classification
6.5.1 Branded Drugs
6.5.2 Generic Drugs
6.6 Market Segmentation By Route Of Administration
6.6.1 Oral
6.6.2 Parenteral
6.6.3 Other Route Of Administration
6.7 Market Segmentation By Mode Of Purchase
6.7.1 Prescription-Based Drugs
6.7.2 Over-The-Counter Drugs
6.8 Market Segmentation By Distribution Channel
6.8.1 Hospital Pharmacies
6.8.2 Retail Pharmacies Or Drug Stores
6.8.3 Other Distribution Channels
7 Major Market Trends
7.1 Enhancing Access To Anti-Angiogenic Therapies Via Biosimilars
7.2 Enhancing Access To Biologic Therapies In Autoimmune Segments
7.3 Supporting Disease Management With Affordable Biologic Solutions
7.4 Advancing High-Concentration Biologic Formulations
7.5 Enhancing Delivery Efficiency In Advanced Therapies
8 Global Biologics Growth Analysis And Strategic Analysis Framework
8.1 Global Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Environmental
8.1.6 Legal
8.2 Analysis Of End Users (B2B Market)
8.2.1 Hospitals
8.2.2 Specialty Clinics
8.2.3 Biopharmaceutical Companies
8.2.4 Contract Research Organizations (CROs)
8.2.5 Home Healthcare Providers
8.2.6 Other End Users
8.3 Global Biologics Market Growth Rate Analysis
8.4 Historic Market Growth, 2019 – 2024, Value ($ Million)
8.4.1 Market Drivers 2019 – 2024
8.4.2 Market Restraints 2019– 2024
8.5 Forecast Market Growth, 2024 – 2029, 2034F Value ($ Million)
8.6 Forecast Growth Contributors/Factors
8.6.1 Quantitative Growth Contributors
8.6.2 Drivers
8.6.3 Restraints
8.7 Global Biologics Total Addressable Market (TAM)
9 Global Biologics Market Segmentation
9.1 Global Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.2 Global Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.3 Global Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.4 Global Biologics Market, Segmentation By Drug Classification, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.5 Global Biologics Market, Segmentation By Mode Of Purchase, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
9.6 Global Biologics Market, Sub-Segmentation Of Monoclonal Antibodies (MAbs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, Value ($ Million)
9.7 Global Biologics Market, Sub-Segmentation Of Therapeutic Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, Value ($ Million)
9.8 Global Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, Value ($ Million)
10 Global Biologics Market, Regional and Country Analysis
10.1 Global Biologics Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
10.2 Global Biologics Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11 Asia-Pacific Market
11.1 Summary
11.2 Market Overview
11.2.1 Region Information
11.2.2 Market Information
11.2.3 Background Information
11.2.4 Government Initiatives
11.2.5 Regulations
11.2.6 Regulatory Bodies
11.2.7 Major Associations
11.2.8 Taxes Levied
11.2.9 Corporate Tax Structure
11.2.10 Investments
11.2.11 Major Companies
11.3 Asia Pacific Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.4 Asia Pacific Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.5 Asia Pacific Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.6 Asia-Pacific Biologics Market: Country Analysis
11.7 China Market
11.8 Summary
11.9 Market Overview
11.9.1 Country Information
11.9.2 Market Information
11.9.3 Background Information
11.9.4 Government Initiatives
11.9.5 Regulations
11.9.6 Regulatory Bodies
11.9.7 Major Associations
11.9.8 Taxes Levied
11.9.9 Corporate Tax Structure
11.9.10 Investments
11.9.11 Major Companies
11.10 China Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.11 China Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.12 China Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.13 India Market
11.14 India Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.15 India Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.16 India Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.17 Japan Market
11.18 Summary
11.19 Market Overview
11.19.1 Country Information
11.19.2 Market Information
11.19.3 Background Information
11.19.4 Government Initiatives
11.19.5 Regulations
11.19.6 Regulatory Bodies
11.19.7 Major Associations
11.19.8 Taxes Levied
11.19.9 Corporate Tax Structure
11.19.10 Investments
11.19.11 Major Companies
11.20 Japan Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.21 Japan Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.22 Japan Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.23 Australia Market
11.24 Australia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.25 Australia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.26 Australia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.27 Indonesia Market
11.28 Indonesia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.29 Indonesia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.30 Indonesia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.31 South Korea Market
11.32 Summary
11.33 Market Overview
11.33.1 Country Information
11.33.2 Market Information
11.33.3 Background Information
11.33.4 Government Initiatives
11.33.5 Regulations
11.33.6 Regulatory Bodies
11.33.7 Major Associations
11.33.8 Taxes Levied
11.33.9 Corporate Tax Structure
11.33.10 Investments
11.33.11 Major Companies
11.34 South Korea Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.35 South Korea Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.36 South Korea Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.37 Bangladesh Market
11.38 Bangladesh Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.39 Bangladesh Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.40 Bangladesh Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.41 Thailand Market
11.42 Thailand Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.43 Thailand Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.44 Thailand Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.45 Vietnam Market
11.46 Vietnam Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.47 Vietnam Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.48 Vietnam Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.49 Malaysia Market
11.50 Malaysia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.51 Malaysia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.52 Malaysia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.53 Singapore Market
11.54 Singapore Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.55 Singapore Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.56 Singapore Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.57 Philippines Market
11.58 Philippines Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.59 Philippines Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.60 Philippines Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.61 Hong Kong Market
11.62 Hong Kong Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.63 Hong Kong Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.64 Hong Kong Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.65 New Zealand Market
11.66 New Zealand Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.67 New Zealand Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
11.68 New Zealand Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12 Western Europe Market
12.1 Summary
12.2 Market Overview
12.2.1 Region Information
12.2.2 Market Information
12.2.3 Background Information
12.2.4 Government Initiatives
12.2.5 Regulations
12.2.6 Regulatory Bodies
12.2.7 Major Associations
12.2.8 Taxes Levied
12.2.9 Corporate tax structure
12.2.10 Investments
12.2.11 Major Companies
12.3 Western Europe Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.4 Western Europe Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.5 Western Europe Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.6 UK Market
12.7 UK Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.8 UK Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.9 UK Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.10 Germany Market
12.11 Germany Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.12 Germany Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.13 Germany Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.14 France Market
12.15 France Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.16 France Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.17 France Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.18 Italy Market
12.19 Italy Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.20 Italy Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.21 Italy Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.22 Spain Market
12.23 Spain Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.24 Spain Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.25 Spain Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.26 Austria Market
12.27 Austria Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.28 Austria Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.29 Austria Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.30 Belgium Market
12.31 Belgium Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.32 Belgium Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.33 Belgium Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.34 Denmark Market
12.35 Denmark Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.36 Denmark Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.37 Denmark Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.38 Finland Market
12.39 Finland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.40 Finland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.41 Finland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.42 Ireland Market
12.43 Ireland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.44 Ireland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.45 Ireland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.46 Netherlands Market
12.47 Netherlands Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.48 Netherlands Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.49 Netherlands Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.50 Norway Market
12.51 Norway Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.52 Norway Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.53 Norway Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.54 Portugal Market
12.55 Portugal Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.56 Portugal Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.57 Portugal Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.58 Sweden Market
12.59 Sweden Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.60 Sweden Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.61 Sweden Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.62 Switzerland Market
12.63 Switzerland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.64 Switzerland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
12.65 Switzerland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13 Eastern Europe Market
13.1 Summary
13.2 Market Overview
13.2.1 Region Information
13.2.2 Market Information
13.2.3 Background Information
13.2.4 Government Initiatives
13.2.5 Regulations
13.2.6 Regulatory Bodies
13.2.7 Major Associations
13.2.8 Taxes Levied
13.2.9 Corporate Tax Structure
13.2.10 Investments
13.2.11 Major Companies
13.3 Eastern Europe Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.4 Eastern Europe Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.5 Eastern Europe Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.6 Russia Market
13.7 Russia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.8 Russia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.9 Russia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.10 Czech Republic Market
13.11 Czech Republic Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.12 Czech Republic Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.13 Czech Republic Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.14 Poland Market
13.15 Poland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.16 Poland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.17 Poland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.18 Romania Market
13.19 Romania Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.20 Romania Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.21 Romania Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.22 Ukraine Market
13.23 Ukraine Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.24 Ukraine Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
13.25 Ukraine Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14 North America Market
14.1 Summary
14.2 Market Overview
14.2.1 Region Information
14.2.2 Market Information
14.2.3 Background Information
14.2.4 Government Initiatives
14.2.5 Regulations
14.2.6 Regulatory Bodies
14.2.7 Major Associations
14.2.8 Taxes Levied
14.2.9 Corporate Tax Structure
14.2.10 Investments
14.2.11 Major Companies
14.3 North America Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.4 North America Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.5 North America Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.6 North America Biologics Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
14.9.1 Country Information
14.9.2 Market Information
14.9.3 Background Information
14.9.4 Government Initiatives
14.9.5 Regulations
14.9.6 Regulatory Bodies
14.9.7 Major Associations
14.9.8 Taxes Levied
14.9.9 Corporate Tax Structure
14.9.10 Investments
14.9.11 Major Companies
14.10 USA Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.11 USA Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.12 USA Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
14.15.1 Country Information
14.15.2 Market Information
14.15.3 Background Information
14.15.4 Government Initiatives
14.15.5 Regulations
14.15.6 Regulatory Bodies
14.15.7 Major Associations
14.15.8 Taxes Levied
14.15.9 Corporate Tax Structure
14.15.10 Investments
14.15.11 Major Companies
14.16 Canada Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.17 Canada Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.18 Canada Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.19 Mexico Market
14.20 Mexico Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.21 Mexico Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
14.22 Mexico Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15 South America Market
15.1 Summary
15.2 Market Overview
15.2.1 Region Information
15.2.2 Market Information
15.2.3 Background Information
15.2.4 Government Initiatives
15.2.5 Regulations
15.2.6 Regulatory Bodies
15.2.7 Major Associations
15.2.8 Taxes Levied
15.2.9 Corporate Tax Structure
15.2.10 Investments
15.2.11 Major Companies
15.3 South America Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.4 South America Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.5 South America Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.6 South America Biologics Market: Country Analysis
15.7 Brazil Market
15.8 Brazil Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.9 Brazil Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.10 Brazil Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.11 Chile Market
15.12 Chile Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.13 Chile Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.14 Chile Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.15 Argentina Market
15.16 Argentina Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.17 Argentina Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.18 Argentina Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.19 Colombia Market
15.20 Colombia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.21 Colombia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.22 Colombia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.23 Peru Market
15.24 Peru Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.25 Peru Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
15.26 Peru Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)
16 Middle East Market
16.1 Summary
16.2 Market Overview
16.2.1 Region Information
16.2.2 Market Information
16.2.3 Background Information
16.2.4 Government Initiatives
16.2.5 Regulations
16.2.6 Regulatory Bodies
16.2.7 Major Associations
16.2.8 Taxes Levied
16.2.9 Corporate Tax Structure
16.2.10 Investments
16.2.11 Major Companies
17 Africa Market
17.1 Summary
17.2 Market Overview
17.2.1 Region Information
17.2.2 Market Information
17.2.3 Background Information
17.2.4 Government Initiatives
17.2.5 Regulations
17.2.6 Regulatory Bodies
17.2.7 Major Associations
17.2.8 Taxes Levied
17.2.9 Corporate Tax Structure
17.2.10 Investments
17.2.11 Major Companies
18 Competitive Landscape And Company Profiles
18.1 Company Profiles
18.2 Pfizer Inc.
18.2.1 Company Overview
18.2.2 Products And Services
18.2.3 Business Strategy
18.2.4 Financial Overview
18.3 Merck & Co. Inc.
18.3.1 Company Overview
18.3.2 Products And Services
18.3.3 Business Strategy
18.3.4 Financial Overview
18.4 F. Hoffmann-La Roche AG
18.4.1 Company Overview
18.4.2 Products And Services
18.4.3 Financial Overview
18.5 Johnson & Johnson
18.5.1 Company Overview
18.5.2 Products And Services
18.5.3 Business Strategy
18.5.4 Financial Overview
18.6 Regeneron Pharmaceutical Inc.
18.6.1 Company Overview
18.6.2 Products And Services
18.6.3 Business Strategy
18.6.4 Financial Overview
19 Other Major And Innovative Companies
19.1 AbbVie Inc.
19.1.1 Company Overview
19.1.2 Products And Services
19.2 Sanofi S.A.
19.2.1 Company Overview
19.2.2 Products And Services
19.3 Amgen Inc.
19.3.1 Company Overview
19.3.2 Products And Services
19.4 AstraZeneca plc
19.4.1 Company Overview
19.4.2 Products And Services
19.5 Bristol Myers Squibb Company
19.5.1 Company Overview
19.5.2 Products And Services
19.6 Eli Lilly and Company
19.6.1 Company Overview
19.6.2 Products And Services
19.7 Fresenius SE & Co. KGaA (Fresenius Kabi)
19.7.1 Company Overview
19.7.2 Products And Services
19.8 Novartis AG
19.8.1 Company Overview
19.8.2 Products And Services
19.9 Takeda Pharmaceuticals Inc.
19.9.1 Company Overview
19.9.2 Products And Services
19.10 Novo Nordisk
19.10.1 Company Overview
19.10.2 Products And Services
19.11 Biogen Inc.
19.11.1 Company Overview
19.11.2 Products And Services
19.12 Samsung biologics Co. Ltd.
19.12.1 Company Overview
19.12.2 Products And Services
19.13 Gilead Sciences Inc.
19.13.1 Company Overview
19.13.2 Products And Services
19.14 Sandoz
19.14.1 Company Overview
19.14.2 Products And Services
19.15 Celltrion, Inc.
19.15.1 Company Overview
19.15.2 Products And Services
20 Competitive Benchmarking
21 Competitive Dashboard
22 Key Mergers And Acquisitions
22.1 Syngene International Acquired Emergent BioSolutions
22.2 Tanvex BioPharma Inc. Acquired Bora Biologics Co. Ltd
22.3 Lonza Acquired Roche
22.4 Ajinomoto Co. Inc Acquired Forge Biologics Holdings LLC
22.5 Samsung Biologics Acquired Samsung Bioepis
23 Recent Developments In Biologics Market
23.1 Enhancing Biologics Production With High-Concentration Formulation Platforms
23.2 Improving Formulation Stability and Injectability
23.3 Enhancing Cancer Care With Long-Acting G-CSF Therapy
24 Opportunities And Strategies
24.1 Global Biologics Market In 2029 – Countries Offering Most New Opportunities
24.2 Global Biologics Market In 2029 – Segments Offering Most New Opportunities
24.3 Global Biologics Market In 2029 – Growth Strategies
24.3.1 Market Trend Based Strategies
24.3.2 Competitor Strategies
25 Biologics Market, Conclusions And Recommendations
25.1 Conclusions
25.2 Recommendations
25.2.1 Product
25.2.2 Place
25.2.3 Price
25.2.4 Promotion
25.2.5 People
26 Appendix
26.1 Geographies Covered
26.2 Market Data Sources
26.3 Research Methodology
26.4 Currencies
26.5 The Business Research Company
26.6 Copyright and Disclaimer

List Of Tables

Table 1: Global Biologics Market, Historic, 2019 – 2024, $ Million
Table 2: Global Biologics Market, Forecast, 2024 – 2029, 2034F, $ Million
Table 3: Global Biologics Market TAM, 2024 And 2034, $ Million
Table 4: Global Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 5: Global Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 6: Global Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 7: Global Biologics Market, Segmentation By Drug Classification, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 8: Global Biologics Market, Segmentation By Mode Of Purchase, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 9: Global Biologics Market, Sub-Segmentation Of Monoclonal Antibodies (MAbs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Table 10: Global Biologics Market, Sub-Segmentation Of Therapeutic Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Table 11: Global Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Table 12: Global Biologics Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 13: Global Biologics Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 14: Asia-Pacific GDP Per Capita, By Country, 2019-2024, $
Table 15: Asia-Pacific Population, By Country, 2019-2029, Millions
Table 16: Asia Pacific Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 17: Asia Pacific Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 18: Asia Pacific Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 19: China GDP Per Capita, 2019-2024, $
Table 20: China Population, 2019-2029, Millions
Table 21: China Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 22: China Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 23: China Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 24: India Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 25: India Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 26: India Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 27: Japan GDP Per Capita, 2019-2024, $
Table 28: Japan Population, 2019-2029, Millions
Table 29: Japan Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 30: Japan Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 31: Japan Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 32: Australia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 33: Australia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 34: Australia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 35: Indonesia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 36: Indonesia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 37: Indonesia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 38: South Korea GDP Per Capita, 2019-2024, $
Table 39: South Korea Population, 2019-2029, Millions
Table 40: South Korea Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 41: South Korea Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 42: South Korea Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 43: Bangladesh Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 44: Bangladesh Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 45: Bangladesh Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 46: Thailand Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 47: Thailand Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 48: Thailand Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 49: Vietnam Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 50: Vietnam Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 51: Vietnam Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 52: Malaysia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 53: Malaysia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 54: Malaysia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 55: Singapore Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 56: Singapore Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 57: Singapore Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 58: Philippines Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 59: Philippines Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 60: Philippines Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 61: Hong Kong Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 62: Hong Kong Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 63: Hong Kong Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 64: New Zealand Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 65: New Zealand Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 66: New Zealand Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 67: Western Europe GDP Per Capita, By Country, 2019-2024, $
Table 68: Western Europe Population, By Country, 2019-2029, Millions
Table 69: Western Europe Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 70: Western Europe Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 71: Western Europe Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 72: UK Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 73: UK Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 74: UK Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 75: Germany Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 76: Germany Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 77: Germany Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 78: France Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 79: France Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 80: France Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 81: Italy Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 82: Italy Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 83: Italy Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 84: Spain Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 85: Spain Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 86: Spain Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 87: Austria Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 88: Austria Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 89: Austria Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 90: Belgium Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 91: Belgium Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 92: Belgium Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 93: Denmark Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 94: Denmark Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 95: Denmark Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 96: Finland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 97: Finland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 98: Finland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 99: Ireland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 100: Ireland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 101: Ireland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 102: Netherlands Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 103: Netherlands Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 104: Netherlands Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 105: Norway Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 106: Norway Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 107: Norway Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 108: Portugal Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 109: Portugal Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 110: Portugal Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 111: Sweden Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 112: Sweden Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 113: Sweden Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 114: Switzerland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 115: Switzerland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 116: Switzerland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 117: Eastern Europe GDP Per Capita, By Country, 2019-2024, $
Table 118: Eastern Europe Population, By Country, 2019-2029, Millions
Table 119: Eastern Europe Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 120: Eastern Europe Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 121: Eastern Europe Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 122: Russia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 123: Russia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 124: Russia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 125: Czech Republic Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 126: Czech Republic Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 127: Czech Republic Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 128: Poland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 129: Poland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 130: Poland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 131: Romania Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 132: Romania Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 133: Romania Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 134: Ukraine Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 135: Ukraine Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 136: Ukraine Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 137: North America GDP Per Capita, By Country, 2019-2024, $
Table 138: North America Population, By Country, 2019-2029, Millions
Table 139: North America Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 140: North America Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 141: North America Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 142: USA GDP Per Capita, 2019-2024, $
Table 143: USA Population, 2019-2029, Millions
Table 144: USA Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 145: USA Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 146: USA Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 147: Canada GDP Per Capita, 2019-2024, $
Table 148: Canada Population, 2019-2029, Millions
Table 149: Canada Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 150: Canada Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 151: Canada Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 152: Mexico Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 153: Mexico Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 154: Mexico Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 155: South America GDP Per Capita, By Country, 2019-2024, $
Table 156: South America Population, By Country, 2019-2029, Millions
Table 157: South America Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 158: South America Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 159: South America Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 160: Brazil Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 161: Brazil Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 162: Brazil Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 163: Chile Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 164: Chile Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 165: Chile Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 166: Argentina Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 167: Argentina Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 168: Argentina Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 169: Colombia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 170: Colombia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 171: Colombia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 172: Peru Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 173: Peru Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 174: Peru Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 175: Middle East GDP Per Capita, By Country, 2019-2024, $
Table 176: Middle East Population, By Country, 2019-2029, Millions
Table 177: Middle East Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 178: Middle East Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 179: Middle East Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 180: Saudi Arabia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 181: Saudi Arabia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 182: Saudi Arabia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 183: Israel Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 184: Israel Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 185: Israel Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 186: Iran Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 187: Iran Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 188: Iran Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 189: Turkey Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 190: Turkey Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 191: Turkey Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 192: UAE Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 193: UAE Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 194: UAE Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 195: Africa GDP Per Capita, By Country, 2019-2024, $
Table 196: Africa Population, By Country, 2019-2029, Millions
Table 197: Africa Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 198: Africa Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 199: Africa Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 200: Egypt Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 201: Egypt Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 202: Egypt Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 203: Nigeria Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 204: Nigeria Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 205: Nigeria Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 206: South Africa Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 207: South Africa Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 208: South Africa Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Table 209: Global Biologics Market, Key Competitor Estimated Market Shares, 2024, Percentage (%)
Table 210: Biologics Market, Competitive Benchmarking (In USD Million)
Table 211: Biologics Market, Competitive Dashboard
Table 212: Global Biologics Market Size Gain ($ Million), 2024 – 2029, By Country
Table 213: Global Biologics Market Size Gain ($ Million), Segmentation By Type, 2024 – 2029
Table 214: Global Biologics Market Size Gain ($ Million), Segmentation By Route Of Administration, 2024 – 2029
Table 215: Global Biologics Market Size Gain ($ Million), Segmentation By Distribution Channel, 2024 – 2029
Table 216: Global Biologics Market Size Gain ($ Million), Segmentation By Drug Classification, 2024 – 2029
Table 217: Global Biologics Market Size Gain ($ Million), Segmentation By Mode Of Purchase, 2024 – 2029
Table 218: Biologics Market Data Sources

List Of Figures

Figure 1: Biologics Market Segmentation By Type
Figure 2: Biologics Market Segmentation By Drug Classification
Figure 3: Biologics Market Segmentation By Route Of Administration
Figure 4: Biologics Market Segmentation By Mode Of Purchase
Figure 5: Biologics Market Segmentation By Distribution Channel
Figure 6: Global Biologics Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
Figure 7: Global Biologics Market, Historic, 2019 – 2024, $ Million
Figure 8: Global Biologics Market, Forecast, 2024 – 2029, 2034F, $ Million
Figure 9: Global Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 10: Global Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 11: Global Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 12: Global Biologics Market, Segmentation By Drug Classification, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 13: Global Biologics Market, Segmentation By Mode Of Purchase, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 14: Global Biologics Market, Sub-Segmentation Of Monoclonal Antibodies (MAbs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Figure 15: Global Biologics Market, Sub-Segmentation Of Therapeutic Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Figure 16: Global Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Figure 17: Global Biologics Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 18: Global Biologics Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 19: Asia Pacific Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 20: Asia Pacific Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 21: Asia Pacific Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 22: China Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 23: China Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 24: China Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 25: India Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 26: India Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 27: India Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 28: Japan Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 29: Japan Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 30: Japan Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 31: Australia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 32: Australia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 33: Australia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 34: Indonesia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 35: Indonesia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 36: Indonesia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 37: South Korea Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 38: South Korea Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 39: South Korea Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 40: Bangladesh Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 41: Bangladesh Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 42: Bangladesh Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 43: Thailand Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 44: Thailand Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 45: Thailand Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 46: Vietnam Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 47: Vietnam Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 48: Vietnam Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 49: Malaysia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 50: Malaysia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 51: Malaysia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 52: Singapore Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 53: Singapore Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 54: Singapore Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 55: Philippines Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 56: Philippines Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 57: Philippines Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 58: Hong Kong Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 59: Hong Kong Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 60: Hong Kong Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 61: New Zealand Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 62: New Zealand Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 63: New Zealand Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 64: Western Europe Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 65: Western Europe Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 66: Western Europe Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 67: UK Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 68: UK Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 69: UK Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 70: Germany Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 71: Germany Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 72: Germany Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 73: France Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 74: France Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 75: France Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 76: Italy Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 77: Italy Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 78: Italy Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 79: Spain Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 80: Spain Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 81: Spain Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 82: Austria Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 83: Austria Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 84: Austria Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 85: Belgium Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 86: Belgium Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 87: Belgium Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 88: Denmark Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 89: Denmark Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 90: Denmark Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 91: Finland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 92: Finland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 93: Finland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 94: Ireland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 95: Ireland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 96: Ireland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 97: Netherlands Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 98: Netherlands Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 99: Netherlands Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 100: Norway Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 101: Norway Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 102: Norway Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 103: Portugal Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 104: Portugal Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 105: Portugal Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 106: Sweden Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 107: Sweden Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 108: Sweden Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 109: Switzerland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 110: Switzerland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 111: Switzerland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 112: Eastern Europe Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 113: Eastern Europe Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 114: Eastern Europe Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 115: Russia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 116: Russia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 117: Russia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 118: Czech Republic Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 119: Czech Republic Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 120: Czech Republic Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 121: Poland Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 122: Poland Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 123: Poland Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 124: Romania Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 125: Romania Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 126: Romania Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 127: Ukraine Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 128: Ukraine Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 129: Ukraine Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 130: North America Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 131: North America Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 132: North America Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 133: USA Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 134: USA Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 135: USA Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 136: Canada Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 137: Canada Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 138: Canada Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 139: Mexico Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 140: Mexico Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 141: Mexico Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 142: South America Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 143: South America Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 144: South America Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 145: Brazil Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 146: Brazil Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 147: Brazil Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 148: Chile Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 149: Chile Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 150: Chile Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 151: Argentina Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 152: Argentina Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 153: Argentina Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 154: Colombia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 155: Colombia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 156: Colombia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 157: Peru Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 158: Peru Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 159: Peru Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 160: Middle East Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 161: Middle East Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 162: Middle East Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 163: Saudi Arabia Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 164: Saudi Arabia Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 165: Saudi Arabia Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 166: Israel Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 167: Israel Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 168: Israel Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 169: Iran Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 170: Iran Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 171: Iran Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 172: Turkey Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 173: Turkey Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 174: Turkey Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 175: UAE Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 176: UAE Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 177: UAE Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 178: Africa Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 179: Africa Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 180: Africa Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 181: Egypt Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 182: Egypt Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 183: Egypt Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 184: Nigeria Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 185: Nigeria Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 186: Nigeria Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 187: South Africa Biologics Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 188: South Africa Biologics Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 189: South Africa Biologics Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
Figure 190: Global Biologics Market, Key Competitor Estimated Market Shares, 2024, Percentage (%)
Figure 191: Geographic Regions Covered

Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Read More About Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Read More About Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

Read More About Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

CRISPR Technology Market - By Product Type (Cas9 And GRNA, Design Tools, Plasmid And Vector), By End-User (Academic Research Organizations, Biopharmaceutical Companies, Agricultural Biotechnology Companies, Contract Rese...

View Report

CRISPR Technology Market - By Product Type (Cas9 And GRNA, Design Tools, Plasmid And Vector), By End-User (Academic Research Organizations, Biopharmaceutical Companies, Agricultural Biotechnology Companies, Contract Rese...

CRISPR Technology Global Market Opportunities And Strategies To 2030: COVID-19 Growth and Change

Purchase Option

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
CRISPR Technology Market Definition
The CRISPR technology market consists of sales of CRISPR technology products and related services by entities (organizations, sole traders and partnerships) that produce CRISPR technology products and equipment. CRISPR is a genome-editing tool. It is used by researchers/healthcare professionals to alter DNA sequences and modify gene function. CRISPR is also used for correcting genetic defects, treating human diseases, and to yield better crop varieties. CRISPR stands for Clusters Of Regularly Interspaced Short Palindromic Repeats. The CRISPR-Cas9 system consists of two key molecules, — Cas9 and guide RNA, that introduce a change or mutation into the DNA at the desired position. The Cas9 is an enzyme that acts as a pair of ‘molecular scissors’ and can cut the two strands of DNA at a specific location in the genome so that bits of DNA can then be added or removed. The guide RNA (gRNA is a small piece of pre-designed RNA sequence (about 20 bases long) located within a longer RNA scaffold. The scaffold part binds to DNA and the pre-designed sequence ‘guides’ Cas9 to the right part of the genome. This makes sure that the Cas9 enzyme cuts at the right point in the genome. High orthogonality, versatility, and efficiency of CRISPR technology make it a preferred genome editing technology.

Anti-Viral Drug Therapy Market - By Drug Class (DNA (Nucleotide) Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Application (HIV, Hepatitis, Herpes, Influenza)...

View Report

Anti-Viral Drug Therapy Market - By Drug Class (DNA (Nucleotide) Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Application (HIV, Hepatitis, Herpes, Influenza)...

Anti-Viral Drug Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Implications And Growth

Purchase Option

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Anti-Viral Drug Therapy Market Definition
The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. The anti-viral drug therapy industry includes establishments that manufacture anti-viral drugs, which are used to treat diseases or illnesses caused by viral infections. Examples of antiviral drugs include idoxuridine, famiciclovir, cidofovir, amantadine, zanamivir, tenofovir, adefovir and ribavirin. Viruses are infective agents comprising of a core of nucleic acids, either RNA or DNA, and are surrounded by a layer of protein. These are not living organisms, and can reproduce only inside a living cell. Anti-viral drugs decrease the ability of viruses to reproduce. These drugs enter the cells infected with virus, and interfere with the ability of the virus to bind to the cell, and stimulate the immune system of the host.

Anti-Viral Drug Therapy Market - By Drug Class (DNA (Nucleotide) Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Application (HIV, Hepatitis, Herpes, Influenza)...

View Report

Anti-Viral Drug Therapy Market - By Drug Class (DNA (Nucleotide) Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Application (HIV, Hepatitis, Herpes, Influenza)...

Anti-Viral Drug Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Implications And Growth

Purchase Option

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Anti-Viral Drug Therapy Market Definition
The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. The anti-viral drug therapy industry includes establishments that manufacture anti-viral drugs, which are used to treat diseases or illnesses caused by viral infections. Examples of antiviral drugs include idoxuridine, famiciclovir, cidofovir, amantadine, zanamivir, tenofovir, adefovir and ribavirin. Viruses are infective agents comprising of a core of nucleic acids, either RNA or DNA, and are surrounded by a layer of protein. These are not living organisms, and can reproduce only inside a living cell. Anti-viral drugs decrease the ability of viruses to reproduce. These drugs enter the cells infected with virus, and interfere with the ability of the virus to bind to the cell, and stimulate the immune system of the host.

Laboratory Information System Global Market Report 2025 – By Product (Standalone LIS, Integrated LIS), By Component (Software, Services), By End User (Hospital Laboratories, Independent Laboratories, Physician Office Lab...

View Report

Laboratory Information System Global Market Report 2025 – By Product (Standalone LIS, Integrated LIS), By Component (Software, Services), By End User (Hospital Laboratories, Independent Laboratories, Physician Office Lab...

Laboratory Information System Global Market Report 2025

Purchase Option

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Laboratory Information System Market Overview
• Laboratory Information System market size has reached to $2.57 billion in 2024 • Expected to grow to $4.21 billion in 2029 at a compound annual growth rate (CAGR) of 11.4% • Growth Driver: Rising Demand For Lab Automation Drives The Laboratory Information System Market • Market Trend: Rising Adoption Of Cloud-Based Laboratory Information Systems • North America was the largest region in 2024 and Western Europe is the fastest growing region.
What Is Covered Under Laboratory Information System Market?
A laboratory information system (LIS) is a computer system that assists in managing many aspects of a medical laboratory, including the input, processing, and storage of information and data. The main product types in laboratory information systems are standalone LIS and integrated LIS. Stand-alone LISs use data models that are developed exclusively for managing laboratory data and activities, and they are fundamentally different from electronic health record (HER) data models. The different components include software, services and are used by various sectors such as hospital laboratories, independent laboratories, physician office laboratories, others.

3D Diagnostic Imaging Services Global Market Report 2025 – By Technique (Ultrasound, MRI, X-ray, Computed Tomography, Other Techniques), By Application (Oncology, Cardiology, Orthopedic, Other Applications), By End User ...

View Report

3D Diagnostic Imaging Services Global Market Report 2025 – By Technique (Ultrasound, MRI, X-ray, Computed Tomography, Other Techniques), By Application (Oncology, Cardiology, Orthopedic, Other Applications), By End User ...

3D Diagnostic Imaging Services Global Market Report 2025

Purchase Option

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
3D Diagnostic Imaging Services Market Overview
• 3D Diagnostic Imaging Services market size has reached to $266.32 billion in 2024 • Expected to grow to $396.67 billion in 2029 at a compound annual growth rate (CAGR) of 8.2% • Growth Driver: Point-Of-Care Testing Driving Growth Of 3D Diagnostic Imaging Services Market • Market Trend: Growing Improved Data Storage And Information Sharing Enhance 3D Diagnostic Imaging Market • North America was the largest region in 2024 and Western Europe is the fastest growing region.
What Is Covered Under 3D Diagnostic Imaging Services Market?
3D diagnostic imaging services include optical imaging of body to visualize internals of body in 3D. These services are used for diagnostic purposes. 3D Diagnostic imaging enables medical professionals to probe within your body in search of signs of a disease. The main techniques of 3D diagnostic imaging services are ultrasound, MRI, X-ray, computed tomography, and others. An ultrasound is a type of imaging test that utilizes sound waves to create images of organs, tissues, and other structures within the body. The various applications include oncology, cardiology, orthopedics, and others that are used by diagnostic centers, hospitals and research centers.

Healthcare Reimbursement Global Market Report 2025 – By Claims (Underpaid, Full Paid), By Payers (Private Payers, Public Payers), By Service Provider (Physician Office, Hospitals, Diagnostic Laboratories, Other Service P...

View Report

Healthcare Reimbursement Global Market Report 2025 – By Claims (Underpaid, Full Paid), By Payers (Private Payers, Public Payers), By Service Provider (Physician Office, Hospitals, Diagnostic Laboratories, Other Service P...

Healthcare Reimbursement Global Market Report 2025

Purchase Option

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Healthcare Reimbursement Market Overview
• Healthcare Reimbursement market size has reached to $13.41 billion in 2024 • Expected to grow to $26.5 billion in 2029 at a compound annual growth rate (CAGR) of 14% • Growth Driver: Rising Costs And Supportive Government Initiatives • Market Trend: Value-Based Care Models In Healthcare Reimbursement • North America was the largest region in 2024 and Western Europe is the fastest growing region.
What Is Covered Under Healthcare Reimbursement Market?
Healthcare reimbursement refers to the payment that hospitals, doctors, and other healthcare providers receive for providing medical services to patients. This payment is often made by health insurance companies, government programs, or by the patient themselves, depending on the coverage. Reimbursement covers costs for various treatments, procedures, tests, and medications, ensuring that providers are compensated for their services and patients can access necessary care without upfront costs. The main claims types of healthcare reimbursement are underpaid, and full paid. The underpaid healthcare reimbursement includes payment for healthcare that is partially reimbursed by the government or insurance companies. The various types of payers include private payers, public payers and involves several service providers such as physician offices, hospitals, diagnostic laboratories, others.

Metabolomics Global Market Report 2025 – By Product & Service (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services), By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Erro...

View Report

Metabolomics Global Market Report 2025 – By Product & Service (Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services), By Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Erro...

Metabolomics Global Market Report 2025

Purchase Option

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Metabolomics Market Overview
• Metabolomics market size has reached to $3.62 billion in 2024 • Expected to grow to $7.92 billion in 2029 at a compound annual growth rate (CAGR) of 17.4% • Growth Driver: Cancer Prevalence Driving Metabolomics Advancements For Early Diagnosis And Treatment • Market Trend: Machine Learning Revolutionizing Metabolomics Advancements In Data Interpretation And Analysis • North America was the largest region in 2024 and Western Europe is the fastest growing region.
What Is Covered Under Metabolomics Market?
Metabolomics is the study of small molecules called metabolites that are produced during metabolism within cells, tissues, or organisms. It provides insights into biological processes, disease mechanisms, and metabolic pathways by analyzing and quantifying these metabolites. This field is crucial in personalized medicine, drug discovery, and understanding various diseases like cancer and diabetes. The main products and services of metabolomics are metabolomics instruments, metabolomics bioinformatics tools, and services. Metabolomics instruments are devices used to extensively examine low-molecular-weight compounds in biological samples. The various metabolomics instruments include separation techniques, detection techniques, and metabolomics bioinformatics tools and services involving bioinformatics tools and databases, as well as bioinformatics services. The different indications are cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others that are applied in biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and others.

Synthetic Biology Global Market Report 2025 – By Technology (Nucleotide Synthesis And Sequencing, Bioinformatics, Microfluidics, Genetic Engineering), By Product Type (Oligonucleotides, Enzymes, Cloning And Assembly Kits...

View Report

Synthetic Biology Global Market Report 2025 – By Technology (Nucleotide Synthesis And Sequencing, Bioinformatics, Microfluidics, Genetic Engineering), By Product Type (Oligonucleotides, Enzymes, Cloning And Assembly Kits...

Synthetic Biology Global Market Report 2025

Purchase Option

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Synthetic Biology Market Overview
• Synthetic Biology market size has reached to $21.13 billion in 2024 • Expected to grow to $53.83 billion in 2029 at a compound annual growth rate (CAGR) of 19.2% • Growth Driver: Synthetic Biology Market Growth Fueled By Rising R&D Investments • Market Trend: Revolutionizing Data Storage: Dna Sequencing Breakthroughs Fuel Investments In Dna Data Storage • North America was the largest region in 2024 and Western Europe is the fastest growing region.
What Is Covered Under Synthetic Biology Market?
Synthetic biology is a field of biological science that involve engineering principles to redesign organisms to give them new abilities. It is possible to think of synthetic biology as the culmination or the prescriptive, deliberate stage of biology. The main product types of synthetic biology are oligonucleotides, enzymes, cloning and assembly kits, xeno-nucleic acids (XNA), and chassis organisms. Oligonucleotides are small single-stranded DNA segments that, when internalized by the cell, can specifically suppress the expression of a single protein. The various technologies include nucleotide synthesis and sequencing, bioinformatics, microfluidics, and genetic engineering that are applied in pharmaceuticals and diagnostics, chemicals, biofuels, bioplastics, and others.

Frequently Asked Questions

What is the definition of the biologics market?

The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics or biosimilars to treat and prevent various microbial diseases and cancers. request a sample here

How will the biologics market drivers and restraints affect biologics market dynamics? What forces will shape the biologics industry going forward?

The biologics market growth is aided by technological advances. However, some biologics market restraints include stringent regulations related to biosimilar approvals. request a sample here

What is the forecast market size of the biologics market?

The biologics market forecast is expected to reach $464,604.9 million in 2023 at a compound annual growth rate of 14.7%. request a sample here

How is the biologics market segmented?

The global biologics market is segmented -
By Type- The biologics market is segmented by type into
a. Monoclonal Antibodies
b. Therapeutic Proteins
c. Vaccines request a sample here

Which region has largest share, and what is the market size and growth by geography according to the biologics global market report?

For more detail on this, request a sample here.

Who are the key players of the global biologics market?

Top competitors in the biologics market are Pfizer Inc; F. Hoffmann-La Roche AG; AbbVie Inc; Merck & Co., Inc; Johnson & Johnson. request a sample here.

What are the key trends in the global biologics market?

Major trends influencing the biologics market include robust research & development request a sample here.

Back to top

Biologics Global Market Opportunities And Strategies To 2034

Biologics Global Market Opportunities And Strategies To 2034

Global Biologics Market

Market Insights